Asthma And COPD Market, By Drug Type (Bronchodilators (Short Acting Bronchodilators, Long Acting Bronchodilators), Anti-Inflammatories (Inhaled Corticosteroids, Leukotriene Modulators and Others), Combination Therapies), By Disease Type (Asthma, and COPD)

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	183 Pages	Coherent Market Insights	March, 2025	CMI20007830

Best Price Guarantee
Price	from $4,500
Length	183 Pages
Publisher	Coherent Market Insights
Published Date	March, 2025
SKU	CMI20007830

Asthma is a condition in which a patient’s airways narrow and swell and may produce extra mucus. This can make breathing difficult and trigger coughing, a whistling sound (wheezing) when a patient breathes out and shortness of breath. For some people, asthma is a minor nuisance, for others, it can be a major problem that interferes with daily activities and may lead to a life-threatening asthma attack. Asthma cannot be cured, but its symptoms can be controlled. Because asthma often changes over time, it's important that a patient works with doctors to track the signs and symptoms and adjust your treatment as needed. COPD is a chronic inflammatory lung disease, in which airways become blocked, leading to wheezing and shortness of breath.

Market Dynamics

The launch of new products is attributed to the growth of the global asthma and COPD market. For instance, in June 2021, GLENMARK PHARMACEUTICALS LTD, a research-based, global pharmaceutical company, launched Tiogiva, a tiotropium bromide dry powder inhaler (DPI) for the treatment of chronic obstructive pulmonary disease (COPD), in the U.K. Tiogiva’s active ingredient, tiotropium bromide, is a bronchodilator— an agent that relaxes airway muscles so they can widen. Due to its bronchodilator properties, tiotropium can ease several COPD symptoms, including shortness of breath, wheezing, coughing, and chest tightness.

Key features of the study:

This report provides an in-depth analysis of the global asthma and COPD market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global asthma and COPD market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AstraZeneca, Novartis AG, GSP plc, Merck & Co., Inc., Verona Pharma plc, Regeneron Pharmaceuticals Inc., and Boehringer Ingelheim International GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding its future product launches, type up-gradation, market expansion, and marketing tactics
Global asthma and COPD market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global asthma and COPD market.

Detailed Segmentation:

Global Asthma And COPD Market, By Drug Type:
By Drug Type
Bronchodilators
Short Acting Bronchodilators
Long Acting Bronchodilators
Anti-Inflammatories
Inhaled Corticosteroids
Leukotriene Modulators
Others
Combined Therapies
Global Asthma And COPD Market, By Disease type:
By Disease Type
Asthma
COPD
Global Asthma And COPD Market, By Dsitribution Channel:
Hospital Pharmacies
Retail Pharemacies
Online Pharmacies
Global Asthma And COPD Market, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
AstraZeneca
Novartis AG
GSP plc,
Merck & Co., Inc.
Verona Pharma plc
Regeneron Pharmaceuticals Inc.
Boehringer Ingelheim International GmbH.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Drug Type; Market Snapshot, By Disease Type; Market Snapshot, By Distribution Channel; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Recent Product Launches; Epidemiology; Merger, Acquisition, and Collaborations; Regulatory Scenario; Key Developments; PEST Analysis
4. Global Asthma And COPD Market– COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Asthma And COPD Market, By Drug Type, 2020–2032, (US$ Bn): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021–2032; Segment Trends; Bronchodilators; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Bn); Short Acting Bronchodilators; Long Acting Bronchodilators; Anti-Inflammatories; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Bn); Inhaled Corticosteroids; Leukotriene Modulators; Others; Combination Therapies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Bn)
6. Global Asthma And COPD Market, By Disease Type, 2020–2032, (US$ Bn): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021–2032; Segment Trends; Asthma; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Bn); COPD; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Bn)
7. Global Asthma And COPD Market, By Distribution Channel, 2020–2032, (US$ Bn): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021–2032; Segment Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Bn); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Bn); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Bn)
8. Global Asthma And COPD Market, By Region, 2020–2032, (US$ Bn): Introduction; Market Share Analysis, By Region, 2025 and 2032 (%); Y-o-Y Growth Analysis, For Regions, 2021–2032; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Bn); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Bn); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Bn); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Bn); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Bn); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Drug type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020–2032, (US$ Bn); North Africa; Central Africa; South Africa
9. Competitive Landscape: AstraZeneca; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Novartis AG; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; GSP plc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Merck & Co., Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Verona Pharma plc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Regeneron Pharmaceuticals Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Boehringer Ingelheim International GmbH; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies
10. Section: ReCAsearch Methodology; About Us; *Browse 34 market data tables and 29 figures on “Asthma and COPD Market”- forecast to 2032

Allergic Asthma Therapeutics Market, By Drug Type (Corticosteroids, Bronchodilators, Leukotriene modifiers, Immunotherapy, Biologics, and Others), By Route of Administration (Oral, Inhaled, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

March, 2025 | Published by: Coherent Market Insights | USD $4,500
Bronchodilators Market Size – By Drug Class (Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators), Route of Administration (Oral, Injectable, Inhaled), Application (Asthma, COPD), Distribution Channel, End-Use – Global Forecast (2024 – 2032)

May, 2024 | Published by: Global Market Insights | USD $4,850
Global Asthma and COPD Drugs Market Size Study & Forecast, by Diseases (Asthma, COPD), by Medication Class (Combination Drugs, Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, Others), and Regional Analysis, 2023-2030

October, 2023 | Published by: Bizwit Research & Consulting | USD $4,950
Inhalable Drugs Market Forecasts to 2030 – Global Analysis By Drug Class (Long-acting Beta Antagonists (LABAs), Inhaled Corticosteroids, Long-acting Muscarinic Antagonists (LAMAs), Leukotriene Modifiers and Other Drug Classes), Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels), Application (Non-respiratory Diseases, Respiratory Diseases and Other Applications) and By Geography

May, 2024 | Published by: Stratistics Market Research Consulting | USD $4,150
Global Inhalable Drugs Market, By Drug Class (Inhaled Corticosteroids, Leukotriene modifiers, Long-acting beta agonists (LABAs), Long-acting muscarinic antagonists (LAMAs), Others), By Product Type (Aerosol, Dry powder Formulation, Spray, Others), By Application (Respiratory Diseases, Non-respiratory Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

March, 2025 | Published by: Coherent Market Insights | USD $4,500
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Corticosteroids, Others), By Route of Administration (Oral and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

February, 2025 | Published by: Coherent Market Insights | USD $4,500

PDF E-mail From Publisher:	$4,500
Site License Fulfilled by Publisher:	$7,000
Global Site License Fulfilled by Publisher:	$10,000

Asthma And COPD Market, By Drug Type (Bronchodilators (Short Acting Bronchodilators, Long Acting Bronchodilators), Anti-Inflammatories (Inhaled Corticosteroids, Leukotriene Modulators and Others), Combination Therapies), By Disease Type (Asthma, and COPD)

Research Assistance

Other tasks

Asthma And COPD Market, By Drug Type (Bronchodilators (Short Acting Bronchodilators, Long Acting Bronchodilators), Anti-Inflammatories (Inhaled Corticosteroids, Leukotriene Modulators and Others), Combination Therapies), By Disease Type (Asthma, and COPD)

Allergic Asthma Therapeutics Market, By Drug Type (Corticosteroids, Bronchodilators, Leukotriene modifiers, Immunotherapy, Biologics, and Others), By Route of Administration (Oral, Inhaled, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Bronchodilators Market Size – By Drug Class (Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators), Route of Administration (Oral, Injectable, Inhaled), Application (Asthma, COPD), Distribution Channel, End-Use – Global Forecast (2024 – 2032)

Global Asthma and COPD Drugs Market Size Study & Forecast, by Diseases (Asthma, COPD), by Medication Class (Combination Drugs, Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, Others), and Regional Analysis, 2023-2030

Research Assistance

Other tasks